WEE1 and acral lentiginous melanoma: performed a retrospective analysis of 114 patients with stages III–IV acral melanoma, with a mean follow-up period of 40 months, and found that 56.1% received systemic adjuvant treatment (consisting of anti-PD-1 therapy, interferon, temozolomide and protein kinase inhibitors), with 48.4% receiving anti-PD-1 therapy (19).